<DOC>
	<DOCNO>NCT00708214</DOCNO>
	<brief_summary>Progression-free rate 16 week BIBW 2992 administration association letrozole</brief_summary>
	<brief_title>BIBW 2992 Letrozole Hormonoresistant Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criterion : Female patient histologically proven breast adenocarcinoma Presence metastatic disease No 2 prior chemotherapy regimens metastatic disease , could include trastuzumab Patients must currently letrozole develop acquire resistance define disease progression letrozole follow previous response ( partial response well , stable disease superior equal 24 week ) Diagnosis disease progression inferior equal 6 week prior trial entrydefined : 1 . Increase number bone lesion bone scan MRI AND/OR 2 . Increased pain area know bony metastasis AND superior equal 2 serial elevation CA 15.3 AND/OR 3 . Progression accord RECIST criterion CT scan , MRI , xray Patients must document menopause confirm estradiol level inferior 11 pg/ml Exclusion criterion : Premenopausal patient Rapidly progressive disease major organ ( i.e . lymphangitic spread lung and/or bulky liver metastasis ) Patient brain metastasis Significant cardiovascular diseases Previous treatment EGFR and/or HER2 inhibit drug ( patient receive trastuzumab chemotherapy letrozole enrol )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>